Search the Newsreel

Freeport-McMoRan (FCX) insider Stephen T. Higgins details stock sale and awards

Freeport-McMoRan insider Stephen T. Higgins reported a stock sale of 7,550 shares for $475,650 on July 30, 2026. The filing also detailed previous equity compensation awards that vested as Restricted Stock Lapse on February 15, 2022 (5,846 shares) and February 15, 2023 (8,431 shares). …

Damora Therapeutics earnings on deck as rare blood cancer race heats up

Damora Therapeutics is set to release its second-quarter earnings, with analysts expecting a loss of 44 cents per share. The pre-revenue biotech is advancing its lead rare blood cancer treatment, DMR-001, towards clinical trials, facing competition from Incyte Corp.'s INCA033989. Investors will focus on …

Freeport-McMoRan, Inc. Revenue Breakdown – SWB:FPMB

This article provides a revenue breakdown for Freeport-McMoRan, Inc. (SWB:FPMB), detailing its top-performing segments and regional contributions. Last year, the company generated ‪22.06 B‬ EUR in revenue, with the Indonesia Operations segment being the largest contributor at ‪7.34 B‬ EUR, and the United States …

Freeport McMoRan (FCX) Stock Trades At A Premium Despite An 89% Return

Freeport-McMoRan (FCX) stock has seen an 88.7% return over five years but is currently considered overvalued based on market multiples and a P/E ratio significantly higher than the industry average. Despite recent gains and a Q2 earnings beat, the stock screens as overvalued, suggesting …

Levi & Korsinsky Notifies Freeport-McMoRan Inc. (FCX) Shareholder

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Freeport-McMoRan Inc. (NYSE:FCX) on behalf of investors who suffered losses. The lawsuit alleges that Freeport-McMoRan made false statements and/or concealed inadequate safety measures at its Grasberg Block Cave mine in Indonesia, leading …

How Investors May Respond To Freeport-McMoRan (FCX) Upgraded Copper-Gold Outlook And Ongoing Buybacks

In July 2026, Freeport-McMoRan reported second-quarter 2026 results showing higher net income and earnings per share year over year, alongside broadly steady sales, and updated guidance forecasting significantly higher copper and gold sales in the second half of 2026 and into 2027. The company …

Securities Fraud Class Action Filed Against Freeport-McMoRan Inc

A securities class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) on behalf of investors who suffered losses between February 15

NovaRed Mining Identifies A Large Copper-Gold Target Beside Hudbay's Producing Copper Mountain Mine

NovaRed Mining (NREDF) has identified two large copper-gold anomalies ten kilometers from Hudbay's (HBM) producing Copper Mountain mine, arguing this discovery is significant for national security given the West's reliance on foreign copper. While NovaRed is a high-risk exploration company with no reserves or …

Dr. Copper Signals Boom As ISM PMI Hits 4-Year High - Global X Copper Miners ETF (ARCA:COPX)

Copper prices have surged nearly 50% in the last 12 months, signaling an economic boom, a phenomenon often referred to as "Doctor Copper." This rise is primarily driven by massive capital spending in AI infrastructure, particularly data centers, which are highly copper-intensive. Recent economic …

Why Is Freeport-McMoRan (NYSE:FCX) in Focus as Gold Steadies on Iran-US Peace Talks?

Freeport-McMoRan (NYSE:FCX) is under renewed scrutiny as gold prices stabilize amidst ongoing Iran-US peace talks. As a significant producer of both copper and gold, the company's performance and market sentiment are heavily influenced by developments in the metals sector and broader geopolitical events. This …

Is Freeport-McMoRan (NYSE:FCX) the Key Mining Stock Today?

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics, Inc. announced that it granted equity awards to six new non-executive employees on August 1, 2026. These inducement grants, approved by the independent Compensation Committee, consist of options to purchase 451,000 ordinary shares with a 10-year term and an exercise price of …

Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA

Perceptive Advisors LLC has acquired a significant stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA), purchasing over 5.1 million shares valued at approximately $9.95 million. This investment represents about 2.75% of the company, contributing to the 47.65% institutional ownership of Neumora Therapeutics. While analyst sentiment is …

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

This article summarizes recent analyst ratings for three healthcare companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY), and Fortrea Holdings Inc. (FTRE). Needham maintained a Buy rating for Bicycle Therapeutics, William Blair maintained a Buy for Alnylam Pharma, and Bank of America Securities maintained a …

Should Freeport-McMoRan’s (FCX) Strong Q2 and Higher Copper-Gold Sales Outlook Require Investor Action?

Freeport-McMoRan (FCX) reported strong Q2 results and projects significantly higher copper and gold sales for the second half of 2026 and into 2027, driven by volume growth. This upgraded sales outlook reinforces the company's volume-driven investment thesis, with copper sales expected to increase over …

Freeport-McMoRan, Inc. Revenue Breakdown – NYSE:FCX

Freeport-McMoRan, Inc. (NYSE:FCX) generated $25.91 billion USD in revenue last year, with its Indonesia Operations segment contributing the most at $8.62 billion USD. Geographically, the United States was the largest contributor, accounting for $9.03 billion USD. The article provides a breakdown of the company's …

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, I

Levi & Korsinsky LLP has announced a class action lawsuit against Neumora Therapeutics, Inc. (NMRA) on behalf of shareholders who suffered losses. The lawsuit alleges that Neumora made false statements and concealed information regarding its Phase Three Program and Phase Two trial data for …

PT Mora Telematika Indonesia Tbk Reports Earnings Results for the Half Year Ended June 30, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $6.57 against a current price of $1.65. While several analysts recently lowered their price targets, the general sentiment remains positive. Institutional investors hold …

Freeport-McMoRan (FCX) Lifted Sales Guidance, Is The Copper Upside Already Priced In?

Freeport-McMoRan (FCX) recently updated its sales guidance for higher copper and gold volumes through 2027, alongside strong Q2 results. Despite a positive market narrative suggesting the stock is undervalued at $70.68 compared to its current $63.44, another perspective notes its P/E ratio of 31x …

Copper Stock Strategy Digs For A 34% Annualized Return As Metal Demand Rises

Freeport-McMoRan stock is holding up reasonably well as the stock market corrects. This options trade aims for income from the copper stock. Continue Reading

BLM seeks public comment on swapping land with Az mining company Freeport

The Bureau of Land Management (BLM) is seeking public comment on a proposed land exchange with Freeport Minerals Corporation, which is part of Freeport-McMoRan. The swap involves exchanging approximately 5,700 acres of BLM land in Graham, Greenlee, and Cochise counties for 25,000 acres held …

FREEPORT-MCMORAN INC SEC Filing (Jul 30, 2026)

This article reports on a Form 144 SEC filing by Freeport-McMoRan Inc. (FCX) on July 30, 2026. The filing indicates a proposed sale of 7,550 shares of common stock, valued at $475,650.00, by an individual who acquired them through a restricted stock lapse on …

Better Mining Stock to Buy Before 2026 Ends: USA Rare Earth vs. Freeport-McMoRan

This article compares USA Rare Earth (USAR) and Freeport-McMoRan (FCX) as mining stock investments, concluding that Freeport-McMoRan is the better option despite USA Rare Earth's higher theoretical upside. While USA Rare Earth offers significant potential returns from its "mine-to-magnet" model, it carries higher risks …

Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating

Wedbush has increased its price target for Damora Therapeutics (DMRA) to $40 from $35, while reiterating an Outperform rating. The company currently holds an average rating of Buy from analysts, with a mean price target of $44.11.

Freeport-McMoRan Inc (FCX) Institutional Confidence

The article provides an overview of Freeport-McMoRan Inc's (FCX) institutional confidence score, which stands at 7.00, placing it 13th out of 127 in the Metals & Mining industry. The institutional shareholding proportion is 88.87%, a slight decrease quarter-over-quarter. Barrow Hanley is identified as the …

Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA

Neumora Therapeutics Inc. (NMRA) Q1 2026 Earnings: Narrower-Than-Expected Loss on Cost Discipline, Shares Slip - Margin Compression Risk

Freeport-McMoRan Inc. stock underperforms Wednesday when compared to competitors

Freeport-McMoRan Inc. (FCX) saw its stock decline by 2.68% on Wednesday, closing at $59.99. This underperformance occurred on a generally negative trading day for the broader market, with both the S&P 500 and Dow Jones Industrial Average also falling. This marks the stock's second …

Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday

Neumora Therapeutics (NMRA) is projected to release its Q2 2026 earnings before market open on August 5th, with analysts anticipating a loss of $0.23 per share. The company previously exceeded estimates with a $0.30-per-share loss. Despite recent target price reductions, analysts maintain a "Moderate …

H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7

H.C. Wainwright has reiterated its Buy rating for Neumora Therapeutics (NMRA.US) and maintained a target price of $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Copper demand fuels gains in leveraged UCOP ETF, but risks remain for long-term holders

Strong demand for copper, driven by its use in electric vehicles, AI, and power infrastructure, is boosting its price in 2026 and leading to gains in the ProShares Ultra Copper K-1 Free ETF (UCOP). While UCOP offers double daily exposure to copper futures, amplifying …

Implied Volatility Surging for Freeport-McMoRan Stock Options

Implied volatility for Freeport-McMoRan Inc. (FCX) stock options, particularly the Sept. 18, 2026 $23 Call, is currently surging, indicating expectations of a significant price movement. This high implied volatility suggests either a major upcoming event or a potential trading opportunity for options traders, despite …

Investors Heavily Search Freeport-McMoRan Inc. (FCX): Here is What You Need to Know

Freeport-McMoRan (FCX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this mining company have …

Neumora Reports Positive Toxicology Data For NMRA-215; IND Planned For Q4 '26

(RTTNews) - Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company, on Monday released positive pre-clinical toxicology data for NMRA-215, an NLRP3 inhibitor developed for treating obesity and cardiometabolic disease. NMRA-215 is an oral drug candidate that shows high brain penetration and targets the NLRP3 …

Freeport-McMoRan (NYSE:FCX) Copper Story Gains Momentum